Antonio Mastroianni Sonia Greco Luciana Chidichimo Filippo Urso Francesca Greco Maria V Mauro Valeria Vangeli
10.1177/20587384211059675
Int J Immunopathol Pharmacol
2021 Jan-Dec;35:20587384211059675.
covid-19 sars-cov-2 biomarkers canakinumab case series interleukin-1β mechanical ventilation
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/34928722/
Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / adverse effects Antibodies, Monoclonal, Humanized / immunology COVID-19 / complications COVID-19 / epidemiology COVID-19 / immunology COVID-19 / therapy Interleukin-1beta / antagonists & inhibitors Interleukin-1beta / immunology Respiration, Artificial / methods Respiration, Artificial / statistics & numerical data
Antibodies, Monoclonal, Humanized / administration & dosage Antibodies, Monoclonal, Humanized / adverse effects Antibodies, Monoclonal, Humanized / immunology COVID-19 / complications COVID-19 / epidemiology COVID-19 / immunology COVID-19 / therapy Interleukin-1beta / antagonists & inhibitors Interleukin-1beta / immunology Respiration, Artificial / methods Respiration, Artificial / statistics & numerical data Observational Study Biomarkers / blood Dose-Response Relationship, Drug Female Humans Inflammation Mediators / blood Italy / epidemiology Male Middle Aged Monitoring, Immunologic / methods Outcome and Process Assessment, Health Care Patient Selection Retrospective Studies SARS-CoV-2 Time-to-Treatment Antibodies, Monoclonal, Humanized Biomarkers IL1B protein, human Inflammation Mediators Interleukin-1beta canakinumab
PMC8725043
34928722
Early use of canakinumab to prevent mechanical ventilation in select COVID-19 patients: A retrospective, observational analysis
2021